Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10502 Combination Treatment in Advanced Solid Tumors
NCT06769425Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-10502 in solid tumor, ovarian cancer, breast cancer and 4 more (7 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Maximum Tolerated Dose, Maximum Applicable Dose and 1 more. Started May 2025; status: recruiting.
02
Drugs
HS-10502
03
Conditions
solid tumorovarian cancerbreast cancerprostate cancer (PCa)gastric cancer (GC)
Beyond the preview
Go deeper on NCT06769425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769425.